- United Kingdom
Background in the development of anti-cancer therapeutics, Astrimmune is also involved in research and development aimed at isolation, characterisation and early diagnosis of circulating tumour cells associated with silent cancers such as pancreatic cancer.
As part of our ongoing R&D cycle, we found that currently available cell segregation technology did not deliver the results of the quality we required. Bringing together our experience and that of manufacturers worldwide, we have developed and optimised Cellexia to address the problems we had encountered using commercially available devices. The result was so effective, we knew that it needed to be commercially avaliable to the entire research community.